Therefore, concurrent treatment with GLP1-RA+SGLT2i appears to exceed the separate administration of each agent regarding changes in biomarkers of oxidative stress and antioxidant ability, respectively, and may be incorporated in the management of high cardiovascular risk T2DM patients earlier in the guidelines’ algorithm. This evidence concerns the gene GCG and type 2 diabetes mellitus.